In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Pfizer’s current price implies a 9.4% upside versus a $30.83 fair value, with valuation methods showing a broad range ($17.67–$42.12), reflecting moderate uncertainty. Financial health scores suggest fair stability but limited growth and efficiency. Monte Carlo analysis indicates high volatility (52.7% CV) and notable downside risk (38.9%), highlighting investment risk amid potential upside.